Aerovate Therapeutics (NASDAQ:AVTE) Sees Large Volume Increase

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) shares saw strong trading volume on Wednesday . 197,194 shares traded hands during trading, an increase of 52% from the previous session's volume of 129,738 shares.The stock last traded at $22.91 and had previously closed at $23.22.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AVTE shares. Wells Fargo & Company reissued an "overweight" rating and set a $35.00 target price on shares of Aerovate Therapeutics in a research note on Monday, April 1st. Wedbush restated an "outperform" rating on shares of Aerovate Therapeutics in a report on Thursday, April 4th. Finally, Jefferies Financial Group initiated coverage on Aerovate Therapeutics in a report on Monday, March 25th. They set a "buy" rating and a $65.00 target price on the stock.

Aerovate Therapeutics Price Performance

The company's 50-day simple moving average is $24.56 and its 200-day simple moving average is $19.35.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings data on Monday, March 25th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.06). Equities analysts forecast that Aerovate Therapeutics, Inc. will post -2.78 EPS for the current year.

Insider Buying and Selling

In other Aerovate Therapeutics news, insider George A. Eldridge sold 2,016 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $25.02, for a total value of $50,440.32. Following the completion of the sale, the insider now owns 1,960 shares in the company, valued at approximately $49,039.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Aerovate Therapeutics news, insider George A. Eldridge sold 2,016 shares of the company's stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $25.02, for a total value of $50,440.32. Following the transaction, the insider now directly owns 1,960 shares of the company's stock, valued at approximately $49,039.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ralph Niven sold 4,600 shares of the firm's stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $17.45, for a total value of $80,270.00. Following the sale, the insider now directly owns 1,609 shares of the company's stock, valued at $28,077.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 83,523 shares of company stock valued at $2,187,172. Corporate insiders own 19.30% of the company's stock.

Hedge Funds Weigh In On Aerovate Therapeutics

Large investors have recently made changes to their positions in the business. Eventide Asset Management LLC acquired a new position in shares of Aerovate Therapeutics in the fourth quarter valued at $276,000. Vestal Point Capital LP acquired a new position in shares of Aerovate Therapeutics in the 4th quarter worth approximately $9,052,000. Alps Advisors Inc. raised its holdings in shares of Aerovate Therapeutics by 11.3% in the 3rd quarter. Alps Advisors Inc. now owns 20,395 shares of the company's stock worth $277,000 after buying an additional 2,075 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Aerovate Therapeutics during the 3rd quarter worth approximately $1,357,000. Finally, Swiss National Bank boosted its stake in Aerovate Therapeutics by 30.9% in the 3rd quarter. Swiss National Bank now owns 21,201 shares of the company's stock valued at $288,000 after buying an additional 5,000 shares in the last quarter.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.